Medlab has already developed two cannabis-based medicines, NanaBis™ and NanaBidial™.
() is set to receive its largest international shipment of cannabis oil to date from Inc. ().
The shipment is part of an agreement between Aphria and Medlab in which Aphria produces and supplies high-yield cannabis extracts for Medlab to be used in human trials.
Trials are testing the management of intractable pain in oncology patients and is the first trial of its kind globally.
For the purposes of the clinical trial, Medlab will receive a specifically designed high-CBD cannabis oil and a high-THC cannabis oil.
READ: Medlab Clinical begins recruitment for phase IIa clinical trial for depression medicine
Medlab will combine the products with its patented medicine delivery system, NanoCelle™.
Medlab’s clinical trial is posited to provide an effective and efficacious pain therapy targeted to advanced cancer pain, that rivals standard opioid use.
The product formulation, manufacturing, and final product validation have met the TGO93 standard set by the Australian Therapeutic Goods Administration (TGA) and permits have been approved by Health Canada.
READ: Medlab Clinical on schedule with medicinal cannabis cancer trial
Medlab’s CEO Dr Sean Hall said: “Trial design, implementation and management is critical to developing a new, accepted drug – the work we are undertaking is to expand the medical toolkit especially with regards to current usage of opioids in patients with intractable pain.
“Trial work is progressing with recruitment underway, further patients accessing the trial product (NanaBis™) under the Australian Special Access Scheme (SAS) is providing early, exciting and promising results.”
